In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on 89bio (ETNB – Research Report), with a price target of $14.00. The company’s shares closed yesterday at $11.47.
Abrahams covers the Healthcare sector, focusing on stocks such as Regeneron, Vertex Pharmaceuticals, and Sarepta Therapeutics. According to TipRanks, Abrahams has an average return of 10.0% and a 50.40% success rate on recommended stocks.
89bio has an analyst consensus of Strong Buy, with a price target consensus of $27.33.
See the top stocks recommended by analysts >>
Based on 89bio’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $34.73 million. In comparison, last year the company had a GAAP net loss of $26.81 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
89bio (ETNB) Company Description:
89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.
Read More on ETNB:
- 89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
- Madrigal opportunity in MASH remains after Boehringer data, says UBS
- Cantor biotech/biopharma analysts to hold analyst/industry conference call
- Biotech Alert: Searches spiking for these stocks today
- 89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
